23 research outputs found
Considerations for application of benchmark dose modeling in radiation research: workshop highlights
publishedVersio
Supersymmetry without R-parity : Constraints from Leptonic Phenomenology
R-parity conservation is an {\it ad hoc} assumption in the most popular
version of the supersymmetric standard model. Most studies of models which do
allow for R-parity violation have been restricted to various limiting
scenarios. The single-VEV parametrization used in this paper provides a
workable framework to analyze phenomenology of the most general theory of SUSY
without R-parity. We perform a comprehensive study of leptonic phenomenology at
tree-level. Experimental constraints on various processes are studied
individually and then combined to yield regions of admissible parameter space.
In particular, we show that large R-parity violating bilinear couplings are not
ruled out, especially for large .Comment: 56 pages Revtex with figures incorporated; typos (including
transcription typo in Table II) and minor corrections; proof-read version, to
appear in Phys. Rev.
Recommended from our members
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer
Linear low-dose extrapolation for noncancer health effects is the exception, not the rule
The nature of the exposure-response relationship has a profound influence on risk analyses. Several arguments have been proffered as to why all exposure-response relationships for both cancer and noncarcinogenic end-points should be assumed to be linear at low doses. We focused on three arguments that have been put forth for noncarcinogens. First, the general “additivity-to-background” argument proposes that if an agent enhances an already existing disease-causing process, then even small exposures increase disease incidence in a linear manner. This only holds if it is related to a specific mode of action that has nonuniversal properties—properties that would not be expected for most noncancer effects. Second, the “heterogeneity in the population” argument states that variations in sensitivity among members ofthe target population tend to “flatten out and linearize” the exposure-response curve, but this actually only tends to broaden, not linearize, the dose-response relationship. Third, it has been argued that a review of epidemiological evidence shows linear or no-threshold effects at low exposures in humans, despite nonlinear exposure-response in the experimental dose range in animal testing for similar endpoints. It is more likely that this is attributable to exposure measurement error rather than a true non-threshold association. Assuming that every chemical is toxic at high exposures and linear at low exposures does not comport to modern-day scientific knowledge of biology. There is no compelling evidence-based justification for a general low-exposure linearity; rather, case-specific mechanistic arguments are needed